Five-year recurrence-free rates of 89.4% and 83.9% indicate durable disease control after ProSense cryoablation in localized ...
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...
IceCure Medical Ltd. announced positive top-line results from its ICESECRET clinical trial of its ProSense cryoablation ...
Laparoscopic and percutaneous approaches have similar short-term efficacy in treating renal tumors. Laparoscopic (LAP) and CT-guided percutaneous (PERC) cryoablation for renal tumors result in similar ...
Percutaneous cryoablation may provide a safe and effective treatment option for patients with renal tumors, new findings suggest. David J. Breen, MD, and colleagues from University Hospitals of ...
IceCure Medical Ltd. (NASDAQ:ICCM), the developer of minimally invasive cryoablation technology that destroys tumors by freezing them, was granted marketing authorization from the U.S. Food and Drug ...
ORLANDO -- Cryoablation without excision for low-risk, early-stage breast cancer may be an option for women over 60, 5-year follow-up results from the ICE3 trial showed. At a mean follow-up of 54.2 ...
CAESAREA, Israel, Oct. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for patients ...
Cryoablation for breast cancer is now included in proposed medical society guidelines for the approved patient population CAESAREA, Israel, Feb. 11, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ...
PFA was noninferior to cryoablation for first recurrence of atrial tachyarrhythmia in patients with paroxysmal atrial fibrillation. Tissue-selective energy delivery and short application times offer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results